Wcn24-2277 Peri-Transplant Desensitization With Apheresis and Rituximab in Kidney Transplant Recipients With Preformed Donor-Specific Antibodies and a Negative CDC Crossmatch. A Single Experience Centre

A significant proportion of kidney transplants show a high HLA sensitization and should be considered for transplantation across the HLA barrier. The best strategy to manage these patients is still a matter of debate and the benefits of desensitization based on apheresis techniques, intravenous immunoglobulins and rituximab have not been clearly delineated.